Inclusion Criteria:

1. Advanced Hepatocellular carcinoma

2. Histologically proven

3. Child-Pugh A and B

4. Age > 18 years.

5. ECOG Performance Status of 0 or1

6. Life expectancy of at least 12 weeks.

7. Subjects with at least one uni-dimensional (for RECIST) or bi-dimensional (for WHO)
measurable lesion. Lesions must be measured by CT-scan or MRI

8. Adequate bone marrow, liver and renal function as assessed by the following

- Hemoglobin > 9.0 g/dl

- Absolute neutrophil count (ANC) >1,500/mm3

- Platelet count ³ 100,000/μl

- Total bilirubin < 1.5 times the upper limit of normal

- ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for
patients with liver involvement of their cancer)

- Alkaline phosphatase < 4 x ULN

- PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically
anticoagulated with an agent such as coumadin or heparin will be allowed to
participate provided that no prior evidence of underlying abnormality in these
parameters exists.]

- Serum creatinine < 1.5 x upper limit of normal. (normal creatinine value:
0.8-1.2 mg/dl)

- Signed and dated informed consent before the start of specific protocol
procedures.

Exclusion Criteria:

1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI
more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring
anti-arrhythmic therapy (beta blockers or Digoxin are permitted) or uncontrolled
hypertension.

2. History of HIV infection

3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0)

4. Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months
from definitive therapy, has a negative imaging study within 4 weeks of study entry
and is clinically stable with respect to the tumor at the time of study entry)

5. Patients with seizure disorder requiring medication (such as steroids or
anti-epileptics)

6. History of organ allograft however, the organ allograft may be allowed as protocol
specific.

7. Patients with evidence or history of bleeding diasthesis

8. Patients undergoing renal dialysis

9. Previous or concurrent cancer that is distinct in primary site or histology from the
cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively
treated > 3 years prior to study entry.

Excluded therapies and medications, previous and concomitant:

1. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study
entry.

2. Major surgery within 4 weeks of start of study

3. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.
[G-CSF and other hematopoietic growth factors may be used in the management of acute
toxicity such as febrile neutropenia when clinically indicated or at the discretion
of the investigator; however they may not be substituted for a required dose
reduction.] [Patients taking chronic erythropoietin are permitted provided no dose
adjustment is undertaken within 2 months prior to the study or during the study]

4. Investigational drug therapy outside of this trial during or within 4 weeks of study
entry

5. Prior exposure to the study drug.

6. Pregnant or breast-feeding patients. Women of childbearing potential must have a
negative pregnancy test performed within 7 days of the start of treatment. Both men
and women enrolled in this trial must use adequate barrier birth control measures
during the course of the trial (and men for at least 3 months after last
administration of study medication). Substance abuse, medical, psychological or
social conditions that may interfere with the patient's participation in the study or
evaluation of the study results

7. Any condition that is unstable or could jeopardize the safety of the patient and
their compliance in the study